Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Goodwill & Intangibles (2018 - 2025)

Rocket Pharmaceuticals' Goodwill & Intangibles history spans 8 years, with the latest figure at $39.2 million for Q4 2025.

  • For Q4 2025, Goodwill & Intangibles fell 39.11% year-over-year to $39.2 million; the TTM value through Dec 2025 reached $39.2 million, down 39.11%, while the annual FY2025 figure was $39.2 million, 39.11% down from the prior year.
  • Goodwill & Intangibles for Q4 2025 was $39.2 million at Rocket Pharmaceuticals, down from $64.3 million in the prior quarter.
  • Across five years, Goodwill & Intangibles topped out at $64.9 million in Q4 2022 and bottomed at $30.8 million in Q1 2021.
  • The 5-year median for Goodwill & Intangibles is $39.2 million (2023), against an average of $45.1 million.
  • The largest annual shift saw Goodwill & Intangibles surged 110.69% in 2022 before it tumbled 39.11% in 2025.
  • A 5-year view of Goodwill & Intangibles shows it stood at $30.8 million in 2021, then skyrocketed by 110.69% to $64.9 million in 2022, then decreased by 0.88% to $64.4 million in 2023, then decreased by 0.07% to $64.3 million in 2024, then crashed by 39.11% to $39.2 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Goodwill & Intangibles are $39.2 million (Q4 2025), $64.3 million (Q3 2025), and $39.2 million (Q2 2025).